Evidence map›Paper›PMID 33050492›Full record

ReviewInternational journal of molecular sciences2020

Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New H

Salvador Harguindey, Khalid Alfarouk, Julián Polo Orozco, Stefano Fais, Jesús Devesa

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Salvador HarguindeyDepartment of Oncology, Institute of Clinical Biology and Metabolism, 01004 Vitoria, Spain.ORCID 0000-0002-1725-757X
Khalid AlfaroukDepartment of Pharmacology, Al-Ghad International Colleges for Applied Medical Sciences, Al-Madinah Al-Munawarah 42316, Saudi Arabia and Alfarouk Biomedical Research LLC, Tampa, FL 33617, USA.ORCID 0000-0001-8656-6117
Julián Polo OrozcoDepartment of Oncology, Institute of Clinical Biology and Metabolism, 01004 Vitoria, Spain.
Stefano FaisDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità (National Institute of Health), 00161 Rome, Italy.
Jesús DevesaScientific Direction, Foltra Medical Centre, 15886 Teo, Spain.ORCID 0000-0002-4153-2543

Funding

The Mercedes Castresana Foundation (Vitoria, Spain) (SH), and the Association for Proton Cancer Research and Treatment (APCRT), Madrid, Spain (JPO, SH). 2020/3
6 · The paper itself

Abstract

A brand new approach to the understanding of breast cancer (BC) is urgently needed. In this contribution, the etiology, pathogenesis, and treatment of this disease is approached from the new pH-centric anticancer paradigm. Only this unitarian perspective, based upon the hydrogen ion (H

Indexed as

ProtonsAnimalsAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsCation Transport ProteinsCell RespirationClinical Studies as TopicCombined Modality TherapyDisease ManagementDrug Resistance, NeoplasmFemaleHumansHydrogenHydrogen-Ion ConcentrationIntracellular SpaceAntineoplastic AgentsBiomarkers, TumorCation Transport ProteinsHydrogenProton Pump InhibitorsProton PumpsProtonsSodium-Hydrogen Exchangersbreast cancer etiopathogenesisbreast cancer treatmentH+-related therapeutics of breast cancerhydrogen ion dynamics of cancerpH-related paradigm

Identifiers

PMID33050492
PMCPMC7589677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.